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Abstract- The lipid accumulation product is a novel, safe and inexpensive index of central lipid over 
accumulation based on waist circumference and fasting concentration of circulating triglycerides. This study 
was designed to investigate the ability of lipid accumulation product to predict Cardio-metabolic risk factors 
in postmenopausal women. In this Cross-sectional study, 264 postmenopausal women by using convenience 
sampling method were selected from menopause clinic in Tehran. Cardio-metabolic risk factors were 
measured, and lipid accumulation product (waist-58×triglycerides [nmol/L]) was calculated. Optimal cut-off 
point of lipid accumulation product for predicting metabolic syndrome was estimated by ROC (Receiver-
operating characteristic) curve analysis. Metabolic syndrome was diagnosed in 41.2% of subjects. Optimal 
cut-off point of lipid accumulation product for predicting metabolic syndrome was 47.63 (sensitivity:75%; 
specificity:77.9%). High lipid accumulation product increases risk of all Cardio-metabolic risk factors except 
overweight, high Total Cholesterol, high Low Density Lipoprotein Cholesterol and high Fasting Blood Sugar 
in postmenopausal women. Our findings show that lipid accumulation product is associated with metabolic 
syndrome and some Cardio-metabolic risk factors Also lipid accumulation product may have been a useful 
tool for predicting cardiovascular disease and metabolic syndrome risk in postmenopausal women. 
© 2016 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran, 2016;54(6):370-375. 
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Introduction 
 
Menopause status has been associated with changes 
in body composition resulting to an increase in central 
adiposity specially visceral fat (1,2). Central adiposity in 
postmenopausal women has been recognized as an 
independent risk for developing metabolic syndrome, 
dyslipidemia, and cardiovascular diseases (CVD) (3). 
Elevated plasma triglycerides (TG) levels have also been 
associated with a higher risk of CVD (4,5). 
The lipid accumulation product (LAP), is a novel, 
safe, and inexpensive index of central lipid over 
accumulation which was first explained by Kahn (2005), 
based on waist circumference and fasting concentration 
of circulating triglycerides: [LAP=(WC-65)×TG for men 
and (WC-58)×TG for women] (6).There are reports of 
different cut-off points at 34.5 and 44.1 for LAP as a 
simple screening tool for insulin resistance, metabolic, 
and cardiovascular risk in young men with polycystic 
ovary syndrome (PCOS) (7,8). 
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This study aimed to investigate the ability of LAP in 
predicting metabolic and cardiovascular risks in 
postmenopausal women. Our other objective was to 
recognize the reliability of LAP as a simple, cost benefit 
index to estimate the prevalence of metabolic syndrome 
(MetS) and cardiovascular risk factors.  
 
Materials and Methods 
 
All menopausal women above 40 years of age who 
have come to the menopause clinic were included in the 
study, which the lack of missed period within a year or 
FSH≥40 was defined as menopause. Those who had 
been under the treatment of drugs specifically lipid 
lowering drugs or have had a history of weight loss 
surgeries or any other kind of procedure that caused 
waist circumference reduction like lipolysis, liposuction, 
abdominoplasty or with a history of coronary heart 
diseases, kidney, and liver diseases have been excluded 
from the study.  
We conducted a cross-sectional study on women 
consulting for climacteric symptoms at the menopause 
clinic of Tehran women general hospital, Tehran, Iran. 
The study was performed from January 2011 to April 
2013 among 264 postmenopausal women in menopause 
clinic. A checklist was completed for each patient; it 
included demographic information, menopausal status, 
medical history, reproductive history, drug history, 
family history, physical examination, and clinical 
laboratory data. Body Mass Index (BMI) was calculated 
by dividing weight (in kilograms) by the square of the 
height (in meters). Waist circumference (WC) was 
measured at a level midpoint between the lower rib 
margin and the top of the iliac crest. Blood pressure 
(BP) was measured twice with a standard 
sphygmomanometer in a sitting position, and the 
average blood pressure had been documented in the 
sheets. After twelve-hour fasting period fasting blood 
glucose (FBG), total cholesterol (TC), high density 
lipoprotein cholesterol (HDL-C) and low- density 
lipoprotein cholesterol (LDL-C), and TG levels were 
determined using an auto-analyzer (Hitachi, 902, Japan).  
MetS was defined according to the National 
Cholesterol Education Program, Adult Treatment Panel 
III (ATPΠΙ) criteria, i.e. having three or more of the 
following components (4): 
1) Abdominal obesity: WC≥88 cm 
2) High TG: serum TG level≥150 mg/dl 
3) Low HDL-C: HDL-C<50 mg/dl 
4) High BP: systolic BP (SBP)≥130 mmHg and/or 
diastolic BP (DBP)≥85mmHg or being on treatment for 
hypertension 
5) High FBG: serum glucose level≥100 mg/dl or 
being on treatment for diabetes 
High TC and High LDL-C were considered as other 
cardio-metabolic risk factors and were defined based on 
ATP III Classification. 
LAP (waist-58×TG [nmol/L]) was calculated after 
the clinical and laboratory evaluations. 
 To determine the optimal threshold for predicting 
MetS risk, the receiver operator characteristic (ROC) 
curve analysis was plotted with an estimation of the 
variables’ sensitivity, specificity. Optimal threshold for 
cardiovascular and metabolic risk factors were assessed 
by the minimum value of 
ඥሺ1 െ sensitivityሻଶ ൅ ሺ1 െ specificityሻଶ (9), which 
represented the maximum sum of sensitivity and 
specificity. 
The area under curve (AUC) relates to the overall 
ability of using the LAP as diagnostic test for predicting 
of cardiovascular and metabolic risks. An AUC value 
range is between0 to 1. The AUC can be interpreted 
according to the following principles: test equal to 
chance (AUC=0.5), less accurate (0.5<AUC≤0.7), 
moderately accurate (0.7<AUC≤0.9), highly accurate 
(0.9<AUC≤1.0), and perfect performance tests 
(AUC=1.0) 10.  
The normality distribution of data was tested by 
Kolomogrov test. Results are shown as means±standard 
deviation (SD) or median and inter quartile range (IQR). 
Mean of baseline characteristics and MetS component 
according to LAP optimal cutoff point was assessed by 
t-test and Mann–Whitney U test. Spearman's rank or 
Pearson's correlation coefficient was calculated between 
variables using a 2-tailed significance test. All data were 
analyzed by SPSS version 16.0 (SPSS Inc, Chicago, IL, 
USA). P<0.05 was considered as statistically significant. 
 
Results 
 
The mean age of participants was 53.98 (SD:5.57) 
years, the mean (SD) age at menopause was 47.23 (5.25) 
years, and the median time since menopause was 5 
(IQR:6) years. MetS was diagnosed in 41.2% of 
individuals. 
ROC curve analysis showed that the AUC was 82.7 
(95%CI:77.5-87.9), and the optimal cut-off point for 
LAP to diagnose MetS risk was 47.63 (sensitivity: 75%; 
specificity:77.9%). Figure 1 shows the ROC of LAP 
index as marker for diagnosing MetS. 
Table 1 shows mean of clinical, anthropometric and 
MetS components according to LAP optimal cut-off 
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point (47.63). As presented in this Table, those 
individuals with higher LAP levels (>47.63) had higher 
WC, hip circumference, SBP; DBP, and TG levels and 
lower HDL-C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Roc curve for LAP index as marker for diagnosing MS 
 
LAP was associated significantly with all cardio-
metabolic risk factors except high TC, high LDL-C and 
high FBS (Table 2). 
Table 3 shows association of LAP with cardio-
metabolic risk factors in logistic regression model. As 
presented in this Table high LAP increase risk of  all 
cardio-metabolic risk factors except overweight, high 
TC, high LDL-C and high FBS. 
A negative correlation was seen between LAP and 
HDL-C levels which is in accordance with Maturana et 
al., findings (11). All these single components, both WC 
and TG levels are associated with dysfunctional and 
highly lipolytic adipose tissue, which is strongly 
associated with MetS, CVD, and type 2 diabetes (12). 
As we reported, a negative correlation existed between 
LAP, TG levels, and WC that shows LAP can well 
reflect the over accumulation of lipids in body, which is 
a major risk factor for cardio-metabolic diseases. E Jike 
et al. also implied that using LAP as a reliable index to 
evaluate cardio-metabolic risks in population is logically 
acceptable because LAP captured both anthropometric 
and metabolic dimensions of visceral fat over 
accumulation (13). 
A positive correlation was seen between WC and 
DBP, which are all important values in cardio metabolic 
diseases. Kahn et Valdez  reported a strong association 
between Glucose and blood pressure with EWET index 
(elevated waist circumference and elevated TG levels), 
which are all risk variables for MetS  and CVD (14). 
Siani et al. also reported a positive association between 
increase in central adiposity (WC) and FBG, serum TG 
levels, which again confirm that simple values like WC 
could be of practical relevance in the assessment of the 
risk associated with the different components of the 
MetS and cardiovascular risk (15). Furthermore, it has 
been reported that WC has a high sensitivity and  
specificity to predict diabetes and cardiovascular events, 
as WC is an indicator of visceral adipose tissue 
Table 1. Mean (SD) of Baseline characteristics & Cardio metabolic risk factors according 
to LAP categories in postmenopausal women 
 All LAP<47.63 LAP≥47.63 P.value 
LAP 53.35(36.13) 30.22(10.22) 83.31(35.66) <0.001 
Age(years) 53.98(5.57) 53.27(5.49) 55(5.59) 0.01 
Time since menopause 
(years) 6.79(6.23) 6.22(5.51) 7.21(6.35) 0.17 
Menopause age(years) 47.23(5.25) 47.03(5.03) 47.78(4.57) 0.21 
BMI(kg/m2) 28.66(44.47) 27.36(4.01) 30.33(4.51) <0.001 
WC(cm) 91.70(13.19) 86.02(9.29) 98.87(13.87) <0.001 
HC(cm 107.51(11.06) 103.56(9) 112.49(11.46) <0.001 
TC(mg/dl) 206.24(48.55) 203.75(48.21) 207.83(47.76) 0.49 
HDL-c(mg/dl) 55.20(14.88) 59.37(15.28) 50.07(10.57) 0.07 
LDL-c(mg/dl) 127.41(60.74) 128.87(75..55) 124.55(32.55) 0.56 
SBP(mmHg) 119.86(18.83) 117.06(20.28) 123.56(16.20) 0.005 
DBP(mmHg) 80.39(12.83) 78.37(12.57) 83(12.80) 0.004 
FPG(mg/dl) 101.70(27.74) 99.97(25.68) 102.81(27.70) 0.38 
TG(mg/dl) 139.63(72.38) 102.04(40.29) 188.02(75.91) <0.001 
LAP: lipid accumulation product; BMI: Body mass index; HDL-c: high density lipoprotein cholesterol; LDL-c: LDL: 
low density lipoprotein cholesterol; TC: Total Cholesterol; SBP: Systolic blood pressure; DBP: Diastolic blood 
pressure; FPG: Fasting plasma glucose; WC: Waist circumference; HC: Hip circumference; TG: triglyceride; 
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associated with increase in plasma free fatty acid, 
leading to hyperinsulinemia and other cardio-metabolic 
risks that could be simply measured (16,17). All these 
evidences show that LAP and WC (as a value measured 
in LAP) are simple, inexpensive and reliable indicators 
of MetS and CVD that could be considered as a useful 
index for CVD risk screening in postmenopausal 
women. 
 
Table 2. Prevalence of cardio metabolic risk factors according to LAP categories in 
postmenopausal women
Cardio metabolic risk 
factors 
All 
n=264 
LAP<47.63 
n=149(55.4%) 
LAP≥47.63 
n=115(42.8%) P.value 
BMI 
Normal 53(20.2) 47(31.8) 6(5.3) 
<0.001 Overweight 120(45.8) 67(45.3) 53(46.5) 
Obese 89(34) 34(23) 55(48.2) 
Abdominal obesity 173(65.5) 69(46.3) 104(90.4) <0.001 
High TG 92(34.8) 20(13.4) 72(62.6) <0.001 
Low HDL 103(39.2) 45(30.4) 58(50.4) 0.001 
High SBP 82(31.2) 36(24.31) 46(40) 0.006 
High DBP 80(30.5) 31(21.1) 49(42.6) <0.001 
High BP 106(40.3) 47(31.8) 59(51.3) 0.001 
High FPG 121(45.8) 61(40.9) 60(52.2) 0.07 
MetS 108(41.2) 27(18.4) 81(70.4) <0.001 
Number 
component 
of MetS 
0 19(7.3) 19(12.9) 0(0) 
<0.001 
1 56(21.4) 48(32.7) 8(7.8) 
2 79(30.2) 53(36.1) 26(22.6) 
3 65(24.8) 23(15.6) 42(36.5) 
4 32(12.2) 4(2.7) 28(24.3) 
5 11(4.2) 0(0) 11(9.6) 
High TC 188(62.5) 92(62.2) 73(63.5) 0.82 
High LDL 132(49.1) 57(49.6) 57(49.6) 0.96 
LAP: lipid accumulation product; BMI: Body mass index; TG: triglyceride; HDL-c: high density lipoprotein cholesterol; 
LDL-c: low density lipoprotein cholesterol; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting 
plasma glucose; MetS: Metabolic Syndrome; TC: Total Cholesterol; 
 
 
 
 
Discussion 
 
In this study, MetS was more prevalent in 
individuals with higher LAP; moreover, those with 
higher LAP had more adverse metabolic components in 
comparison with subjects with lower LAP. Different 
studies have shown an association between LAP level, 
metabolic and cardiovascular risk factors (6,11,18). 
Previous studies show that higher WC and elevated 
TG levels can be a predictor of higher metabolic and 
CVD risks (12,14,19). Others showed an association 
between menopausal status and central adiposity, which 
is a great risk for cardiovascular events and metabolic 
disturbances (20,21). LAP was first explained by Kahn. 
in a study using data from NHANES ΠΙ database in 
2005, which was a comparison between LAP and BMI 
to predict CVD, MetS, and diabetes risk. This study 
showed that LAP might be a better predictor of the 
incidence of CVD (6). Also, an increased risk of 
mortality with higher LAP was reported in a study on 
postmenopausal healthy women (8). Our findings also 
show an association between higher LAP and the 
prevalence of MetS and other metabolic and 
cardiovascular risks as higher WC, elevated TG and 
lower HDL-C levels. These suggest that LAP may have 
clinical application, to be a useful tool for CVD risk 
screening especially in postmenopausal women with 
obesity. Taverna et al., also have shown that LAP could 
be an accurate predictor of the MetS in adults (18). 
Table 3. Association between LAP and cardio 
metabolic risk factors in logistic regression analysis 
Cardio metabolic risk 
factors 
LAP(>47.63/<47.63) 
OR adjusted* (95%CI) P.Value 
High SBP 1.84(1.1-3.21) 0.02 
High DBP 2.68(1.55-4.64) <0.001 
HTN 2.07(1.24-3.47) 0.005 
Low HDL 2.38(1.42-3.99) 0.001 
Overweight 1.06(0.65-1.74) 0.81 
Obesity 3.12(1.82-5.34) <0.001 
High FBS 1.55(0.95-2.55) 0.08 
High TC 0.98(0.59-1.64) 0.95 
High LDL 0.97(0.59-1.59) 0.96 
MetS 10.45(5.83-18.75) <0.001 
LAP: lipid accumulation product; SBP: Systolic blood pressure; DBP: 
Diastolic blood pressure; HDL-c: high density lipoprotein cholesterol; 
FPG: Fasting plasma glucose; LDL-c: low density lipoprotein 
cholesterol; TC: Total Cholesterol; MetS: Metabolic Syndrome 
*adjusted for age 
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We showed a cut-off point of 48.61 as a reliable 
point to diagnose in postmenopausal women. To the best 
of our knowledge, no previous report about the best cut-
off point of LAP for predicting in postmenopausal 
women. Wiltgen et al., report a cut-off point of 34.5 as a 
useful, cost benefit tool to screen CVD risk in young 
women with PCOS (7). In another study, Wehr et al. 
suggested a cut-off point of 44.1 for screening the risk of 
impaired glucose tolerance in PCOS women (22). 
Taverna et al., also used a cut-off value of 48.09 in men 
and 31.77 in women, for risk assessment of MetS in 
healthy population (18). 
This study has some limitations; first small 
population study might influence our results.  
Furthermore, this study has been performed only on a 
limited population in Tehran, which may not be 
contributable to other regions of country or other 
ethnicities. 
This study shows that LAP index is associated with 
MetS in postmenopausal women. Individuals with 
higher LAP index had an increased risk of metabolic 
disorders compared to those with lower LAP. This index 
may be a strong, reliable and low cost tool for screening 
metabolic syndrome in postmenopausal population. 
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